| A phase IIB trial of BCG combined with interferon alpha for bladder cancer K Esuvaranathan, R Kamaraj, RS Mohan, C Cheng, PK Tan, KP Tay J Urol 163 (4 Supplement), 2000 | 13 | 2000 |
| MP56-19 LONG TERM RESULTS OF A DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL OF INTERFERON ALPHA-2B AND LOW DOSE BCG IN PATIENTS WITH HIGH RISK NON-MUSCLE-INVASIVE BLADDER CANCER K Esuvaranathan, SM Tham, M Ravuru, R Kamaraj, TP Ng, YH Chan, ... The Journal of Urology 191 (4S), e571-e571, 2014 | 6 | 2014 |
| Advances in Cancer Management K McNagny, M Hughes, M Graves, E Debruin, K Snyder, J Cipollone, ... InTech, London, UK, 2012 | 6 | 2012 |
| Long term results of a double-blind randomised controlled trial of interferon alpha-2b and low dose BCG in patients with high risk non-muscle-invasive bladder cancer K Esuvaranathan, SM Tham, M Ravuru, R Kamaraj, TP Ng, YH Chan, ... BJU INTERNATIONAL 113, 1-1, 2014 | 2 | 2014 |
| A retrospective review of our clinical experience in the use of Mirabegron for management of overactive bladder symptoms in the elderly RS Mohan AUSTRALASIAN JOURNAL ON AGEING 38, 53-54, 2019 | | 2019 |
| Long term results of BCG and interferon alpha for high risk superficial bladder cancer K Esuvaranathan, R Mohan, R Kamaraj, TP Ng, WS Cheng, SJ Chia, ... Cancer Research 67 (9_Supplement), 1867-1867, 2007 | | 2007 |
| INTRAVESICAL BACILLUS CALMETTE-GUERIN (BCG) AND INTERFERON ALPHA-2B IN THE TREATMENT OF SUPERFICIAL BLADDER CANCER-A CLINICAL AND IMMUNOLOGICAL STUDY RS Mohan | | 1999 |
